- Home
- GRI vs GNLN Comparison
GRI vs GNLN Comparison
Compare GRI & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- GNLN
- Stock Information
- Founded
- GRI 2018
- GNLN 2005
- Country
- GRI United States
- GNLN United States
- Employees
- GRI N/A
- GNLN N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- GNLN Durable Goods
- Sector
- GRI Health Care
- GNLN Consumer Discretionary
- Exchange
- GRI Nasdaq
- GNLN Nasdaq
- Market Cap
- GRI 1.5M
- GNLN 2.8M
- IPO Year
- GRI N/A
- GNLN 2019
- Fundamental
- Price
- GRI $0.47
- GNLN $4.32
- Analyst Decision
- GRI Strong Buy
- GNLN
- Analyst Count
- GRI 1
- GNLN 0
- Target Price
- GRI $12.00
- GNLN N/A
- AVG Volume (30 Days)
- GRI 2.6M
- GNLN 78.3K
- Earning Date
- GRI 11-13-2024
- GNLN 08-14-2024
- Dividend Yield
- GRI N/A
- GNLN N/A
- EPS Growth
- GRI N/A
- GNLN N/A
- EPS
- GRI N/A
- GNLN N/A
- Revenue
- GRI N/A
- GNLN $29,367,000.00
- Revenue This Year
- GRI N/A
- GNLN $72.27
- Revenue Next Year
- GRI N/A
- GNLN $93.46
- P/E Ratio
- GRI N/A
- GNLN N/A
- Revenue Growth
- GRI N/A
- GNLN N/A
- 52 Week Low
- GRI $0.30
- GNLN $2.05
- 52 Week High
- GRI $134.68
- GNLN $21.80
- Technical
- Relative Strength Index (RSI)
- GRI 49.35
- GNLN 43.46
- Support Level
- GRI $0.36
- GNLN $4.06
- Resistance Level
- GRI $0.55
- GNLN $4.66
- Average True Range (ATR)
- GRI 0.06
- GNLN 0.30
- MACD
- GRI 0.02
- GNLN 0.02
- Stochastic Oscillator
- GRI 56.28
- GNLN 24.53
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a distributor of vaporization products and consumption accessories in the United States. It offers a selection of stock-keeping units including vaporizers and parts, cleaning products, grinders and storage containers, pipes, rolling papers and customized lines of premium specialty packaging. The company markets and sells its products in both the business to business and business to consumer sectors of the marketplace. Its geographical segment includes the United States; Canada and Europe. It derives a majority of revenue from the United States.